Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
暂无分享,去创建一个
N. Schultz | B. A. Aksoy | D. Park | Soo-Jeong Cho | S. Ryeom | Sam S. Yoon | C. Yoon | Sam S. Yoon
[1] A. Ardizzoni,et al. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations , 2015, Molecular Cancer Therapeutics.
[2] Yongning Zhou,et al. Stem cells in gastric cancer. , 2015, World journal of gastroenterology.
[3] V. Sanz-Moreno,et al. Rho GTPases modulate malignant transformation of tumor cells , 2014, Small GTPases.
[4] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[5] Hae-June Lee,et al. CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance , 2014, Clinical Cancer Research.
[6] Junjiang Fu,et al. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer , 2014, Tumor Biology.
[7] Shibing Deng,et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.
[8] Atsushi Tanaka,et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.
[9] R. Pi,et al. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. , 2013, European journal of medicinal chemistry.
[10] Min Chen,et al. Dynamic functions of RhoA in tumor cell migration and invasion , 2013, Small GTPases.
[11] A. Wotherspoon,et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.
[12] Galina Kurteva,et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.
[13] L. Nicholson,et al. Cancer stem cells: in the line of fire. , 2012, Cancer treatment reviews.
[14] Julian Downward,et al. The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer , 2012, Cell.
[15] M. El-Sibai,et al. Rho GTPases in primary brain tumor malignancy and invasion , 2012, Journal of Neuro-Oncology.
[16] F. Ciardiello,et al. Current status of targeted therapies in advanced gastric cancer , 2012, Expert opinion on therapeutic targets.
[17] G. Nardone,et al. Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. , 2012, World journal of gastrointestinal oncology.
[18] Khay Guan Yeoh,et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets , 2012, Gut.
[19] D. Radisky,et al. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. , 2012, Cold Spring Harbor perspectives in biology.
[20] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. McCubrey,et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. , 2011, Current medicinal chemistry.
[22] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[23] R. Karlsson,et al. Rho GTPase function in tumorigenesis. , 2009, Biochimica et biophysica acta.
[24] I. Bisson,et al. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics , 2009, Cell Research.
[25] T. Wang,et al. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.
[26] Jun Liang,et al. Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters , 2009, Clinical chemistry and laboratory medicine.
[27] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[28] Masaru Miyazaki,et al. The Activity of RhoA is Correlated with Lymph Node Metastasis in Human Colorectal Cancer , 2008, Digestive Diseases and Sciences.
[29] B. Alicke,et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models , 2006, Molecular Cancer Therapeutics.
[30] J. Haerting,et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Huntsman,et al. Gastric cancer: New genetic developments , 2005, Journal of surgical oncology.
[32] Y. Hirooka,et al. Therapeutic Potential of Rho-Kinase Inhibitors in Cardiovascular Diseases , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[33] X. Yao,et al. Expression of seven main Rho family members in gastric carcinoma. , 2004, Biochemical and biophysical research communications.
[34] Cristián Zegers Ariztía,et al. Manual , 2002 .
[35] H. Hidaka,et al. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. , 2002, Pharmacology & therapeutics.
[36] D. Gingras,et al. Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. , 2002, The Biochemical journal.
[37] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[38] E. Lengyel,et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] Ukcccr. UKCCCR Guidelines for the Use of Cell Lines in Cancer Research , 2000, British Journal of Cancer.
[40] T. Pawlik,et al. Mouse endostatin inhibits the formation of lung and liver metastases. , 1999, Cancer research.
[41] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[42] P. Laurén,et al. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.
[43] H. Gaylord,et al. AMERICAN ASSOCIATION FOR CANCER RESEARCH. , 1913, California state journal of medicine.